La vendita allo scoperto per DocGo dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di DocGo. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

DocGo (NASDAQ:DCGO) Azioni, Report sulle vendite allo scoperto

DocGo

DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.

DocGo Inc

Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 by 20 percent. The company reported quarterly sales of $315.119 million which beat the analyst consensus estimate of $310.218 million by 1.58 percent. This is a 28.75 percent decrease over sales of $442.291 million the same period last year.

Earnings

Earnings Beats

News

CCRN

Cross Country Healthcare Q3 2024 Adj. EPS $0.12 Beats $0.10 Estimate, Revenue From Services $315.119M Beat $310.218M Estimate

GFL Environmental Q3 2024 Adj. EPS C$0.23 Misses C$0.35 Estimate, Sales C$2.015B Miss C$2.052B Estimate

Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.29 by 20.69 percent. The company reported quarterly sales of $581.00 million which beat the analyst consensus estimate of $554.68 million by 4.75 percent. This is a 17.14 percent increase over sales of $496.00 million the same period last year.

Zillow Gr Q3 2024 Adj EPS $0.35 Beats $0.29 Estimate, Sales $581.00M Beat $554.68M Estimate

Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.42 by 2.38 percent. The company reported quarterly sales of $2.653 billion which beat the analyst consensus estimate of $2.485 billion by 6.76 percent. This is a 3.67 percent increase over sales of $2.559 billion the same period last year.

Williams Companies Q3 2024 Adj. EPS $0.43 Beats $0.42 Estimate, Sales $2.653B Beat $2.485B Estimate

CS Disco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAW#NYSE">LAW</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $36.27 million which missed the analyst consensus estimate of $36.33 million by 0.18 percent. This is a 3.79 percent increase over sales of $34.94 million the same period last year.

Earnings Misses

CS Disco Q3 Adj $(0.06) Beats $(0.09) Estimate, Sales $36.27M Miss $36.33M Estimate

Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) raises FY2024 sales outlook from $1.05 billion-1.13 billion to $1.06 billion-1.13 billion.

Guidance

Emergent BioSolutions Raises FY2024 Sales Guidance from $1.05B-1.13B to $1.06B-1.13B

Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) reported quarterly earnings of $1.80 per share which beat the analyst consensus estimate of $1.57 by 14.65 percent. The company reported quarterly sales of $1.305 billion which beat the analyst consensus estimate of $1.267 billion by 3.01 percent. This is a 10.03 percent increase over sales of $1.186 billion the same period last year.

Marriott Vacations Q3 2024 Adj. EPS $1.80 Beats $1.57 Estimate, Sales $1.305B Beat $1.267B Estimate

TKO Group Holdings Sees FY24 Revenue To Upper End Of $2.67B-$2.745B Vs $2.758B Est.

Buybacks

AMPH

Amphastar Pharmaceuticals Expands Share Buyback Program By $50M To Offset Equity Compensation Dilution, With No Set End Date

SLR Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRC#NASDAQ">SLRC</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.42 by 7.14 percent. The company reported quarterly sales of $59.771 million which beat the analyst consensus estimate of $57.979 million by 3.09 percent. This is a 0.22 percent increase over sales of $59.641 million the same period last year.

SLRC

SLR Inv Q3 2024 GAAP EPS $0.45 Beats $0.42 Estimate, Sales $59.771M Beat $57.979M Estimate

A-Mark Precious Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) reported quarterly earnings of $0.37 per share which missed the analyst consensus estimate of $0.87 by 57.47 percent. The company reported quarterly sales of $2.715 billion which beat the analyst consensus estimate of $2.622 billion by 3.53 percent. This is a 9.26 percent increase over sales of $2.485 billion the same period last year.

AMRK

A-Mark Precious Metals Q1 2025 Adj. EPS $0.37 Misses $0.87 Estimate, Sales $2.715B Beat $2.622B Estimate

Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) is looking for Q4 Adj EPS of $0.32-0.52 vs $0.31 analyst estimate. seessales of $88.000 million-96.000 million vs $91.55 million estimate.

FARO

Faro Technologies Sees Q4 Adj EPS $0.32-0.52 vs $0.31 Est; Sees Sales $88.000M-96.000M vs $91.55M Est

Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) is looking for Q4 GAAP EPS of $(0.15)-0.05 vs $0.01 analyst estimate..

Faro Technologies Sees Q4 GAAP EPS $(0.15)-0.05 vs $0.01 Est

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) reported quarterly earnings of $0.96 per share which missed the analyst consensus estimate of $0.99 by 3.03 percent. The company reported quarterly sales of $191.20 million which missed the analyst consensus estimate of $194.69 million by 1.79 percent. This is a 5.90 percent increase over sales of $180.56 million the same period last year.

Amphastar Pharma Q3 2024 Adj EPS $0.96 Misses $0.99 Estimate, Sales $191.20M Miss $194.69M Estimate

ZipRecruiter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIP#NYSE">ZIP</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.09) by 66.67 percent. The company reported quarterly sales of $117.084 million which beat the analyst consensus estimate of $112.612 million by 3.97 percent. This is a 24.77 percent decrease over sales of $155.630 million the same period last year.

ZipRecruiter Q3 2024 GAAP EPS $(0.03) Beats $(0.09) Estimate, Sales $117.084M Beat $112.612M Estimate

The Company has identified and intends to realize annualized G&amp;A and operating expense savings of between $15 million and $20 million on a run-rate basis from the restructuring.
&nbsp;

Management

Sun Communities Plans Restructuring, John McLaren Returning As President; CEO Gary Shiffman Informs His Intention To Retire In 2025

Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.08 by 37.5 percent. The company reported quarterly sales of $186.600 million which beat the analyst consensus estimate of $181.637 million by 2.73 percent. This is a 21.52 percent increase over sales of $153.550 million the same period last year.

FRSH

Freshworks Q3 2024 Adj. EPS $0.11 Beats $0.08 Estimate, Sales $186.600M Beat $181.637M Estimate

EHAB

Enhabit Sees FY24 Adj. EPS $0.19-$0.29 Vs $0.27 Est.; Revenue $1.031B-$1.046B Vs 1.054B Est.

Stock Split

Signing Day Sports Announced A 1-48 Reverse Stock Spilt Effective On November 16, 2024

Innovate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) reported quarterly losses of $(1.18) per share. This is a 31.11 percent decrease over losses of $(0.90) per share from the same period last year. The company reported $242.20 million in sales this quarter. This is a 35.46 percent decrease over sales of $375.30 million the same period last year.

VATE

Innovate Q3 EPS $(1.18) Down From $(0.90) YoY, Sales $242.20M Down From $375.30M YoY

DocGo Inc. (DCGO) Q2 2024 Earnings Call Transcript

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Curaleaf Holdings (CURLF – Research Report) and DocG...

Analysts Offer Insights on Healthcare Companies: Curaleaf Holdings (OtherCURLF) and DocGo (DCGO)

Canaccord Genuity analyst Richard Close has maintained their bullish stance on DCGO stock, giving a Buy rating today. Richard Close has given his B...

Buy Rating Affirmed for DocGo on Strong Quarterly Performance and Positive Growth Trajectory

DocGo (DCGO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on August 7. Analyst Pito Chickering from Deu...

DocGo: A Strong Buy on Robust Financial Performance and Growth Prospects

Northland Securities analyst Michael Latimore maintained a Buy rating on DocGo (DCGO – Research Report) today and set a price target of $8.00. The ...

Northland Securities Sticks to Its Buy Rating for DocGo (DCGO)

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 8/26/2024, According to Top Analysts

The latest announcement is out from DocGo ( ($DCGO) ). DocGo Inc. has announced the appointment of Dr. Stephen K. Klasko as the new Chair of its Bo...

DocGo Appoints Dr. Stephen Klasko as New Board Chair

DocGo appoints Stephen Klasko as chair

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on DocGo (DCGO – Research Report), Avidity Biosciences ...

Analysts' Top Healthcare Picks: DocGo (DCGO), Avidity Biosciences (RNA)

Ambulnz by DocGo and Bayhealth renew partnership, extending contract for three years

CURLF

DCGO

OPRA

RARE

Press Releases

DocGo Launches Mobile X-Ray Program in Partnership with MinXray

DocGo Announces Strong Second Quarter 2024 Results

DocGo Announces Participation at Four Upcoming Investor Conferences

DocGo Expands Care Gap Closure Program to Enhance Healthcare Access for Hundreds of Thousands of Medicaid Recipients in California

DocGo Named Finalist for National Compliance Awards

DocGo Appoints Eiwe Lingefors as New Chief Information Officer

DocGo Appoints Healthcare Visionary Dr. Stephen K. Klasko as Chair of the Board

Ambulnz by DocGo and Bayhealth Renew Partnership in Delaware, Extending Contract for Three Years

DocGo to Announce Third Quarter 2024 Results on Thursday, November 7, 2024

Kuehn Law Encourages Investors of DocGo, Inc. to Contact Law Firm

Accolade

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

Castle Biosciences

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Fulgent Genetics

InnovAge Holding

23andMe Holding

ModivCare

National Research Corporation - Common Stock

National Research

Nutex Health

OPKO Health

Performant Financial Corporation - Common Stock

Performant Finl

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Pennant Gr

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

SBC Medical Group Holdings Incorporated - Common Stock

SBC Medical Group Holding

SHL Telemedicine Ltd - American Depositary Shares

Comments

DocGo

Vendite allo scoperto

DocGo (NASDAQ:DCGO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO